Andrew Lewin

5.6k total citations · 2 hit papers
57 papers, 4.3k citations indexed

About

Andrew Lewin is a scholar working on Endocrinology, Diabetes and Metabolism, Cardiology and Cardiovascular Medicine and Surgery. According to data from OpenAlex, Andrew Lewin has authored 57 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Endocrinology, Diabetes and Metabolism, 23 papers in Cardiology and Cardiovascular Medicine and 16 papers in Surgery. Recurrent topics in Andrew Lewin's work include Diabetes Treatment and Management (22 papers), Blood Pressure and Hypertension Studies (20 papers) and Diabetes Management and Research (13 papers). Andrew Lewin is often cited by papers focused on Diabetes Treatment and Management (22 papers), Blood Pressure and Hypertension Studies (20 papers) and Diabetes Management and Research (13 papers). Andrew Lewin collaborates with scholars based in United States, Germany and Denmark. Andrew Lewin's co-authors include Bruce W. Bode, Philip Raskin, Ralph A. DeFronzo, Sherwyn Schwartz, Richard M. Bergenstal, Bernard Zinman, Robert F. Kushner, Melanie J. Davies, Christine B. Jensen and Trine Vang Skjøth and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Andrew Lewin

55 papers receiving 4.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes

2015 793 citations Bruce W. Bode, Andrew Lewin et al. profile →
Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)

2009 707 citations Bernard Zinman, Andrew Lewin et al. Diabetes Care profile →

Peers

Countries citing papers authored by Andrew Lewin

Since Specialization

Citations

This map shows the geographic impact of Andrew Lewin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Lewin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Lewin more than expected).

Fields of papers citing papers by Andrew Lewin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Lewin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Lewin. The network helps show where Andrew Lewin may publish in the future.

Co-authorship network of co-authors of Andrew Lewin

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Lewin. A scholar is included among the top collaborators of Andrew Lewin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Lewin. Andrew Lewin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Blood pressure-lowering effects of nifedipine/candesartan combinations in high-risk individuals: subgroup analysis of the DISTINCT randomised trial 2016 ·Journal of Human Hypertension ·(unknown), Giuseppe Mancia, (unknown), Blas Gil Extremera, Peter Harvey, Andrew Lewin, Giuseppe Villa, Sverre E. Kjeldsen	3
2	Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin 2015 ·Diabetes Care ·Ralph A. DeFronzo, Andrew Lewin, Sanjay Patel, Dacheng Liu, Renee Kaste, Hans J. Woerle, Uli C. Broedl	244
3	Combined Olmesartan, Amlodipine, and Hydrochlorothiazide Therapy in Randomized Patients with Hypertension: A Subgroup Analysis of the TRINITY Study by Age 2013 ·Drugs & Aging ·Andrew Lewin, Joseph L. Izzo, Michael Melino, James Lee, (unknown), Reinilde Heyrman	8
4	Nebivolol Monotherapy for Patients With Systolic Stage II Hypertension: Results of a Randomized, Placebo-Controlled Trial 2013 ·Clinical Therapeutics ·Andrew Lewin, Henry Punzi, Xiaohui Luo, (unknown)	9
5	Efficacy/Safety of Olmesartan Medoxomil Versus Losartan Potassium in Naïve Versus Previously Treated Subjects With Hypertension 2012 ·Advances in Therapy ·Henry Punzi, Andrew Lewin, Wei Li, (unknown)	9
6	Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial 2011 ·The Lancet ·Bernard Zinman, Greg Fulcher, Paturi Vishnupriya Rao, Nihal Thomas, Lars Endahl, Thue Johansen, (unknown), Andrew Lewin, Julio Rosenstock, M. Pinget, Chantal Mathieu	101
7	Insulin degludec, a new generation ultra-long acting insulin, used once daily or 3-times weekly in people with type 2 diabetes: comparison to insulin glargine 2010 ·Diabetes ·Bernard Zinman, Greg Fulcher, (unknown), Nihal Thomas, Lars Endahl, Thue Johansen, Andrew Lewin, Julio Rosenstock, M. Pinget, Chantal Mathieu	5
8	Acetylsalicylic Acid Reduces Niacin Extended-Release-Induced Flushing in Patients with Dyslipidemia 2009 ·American Journal of Cardiovascular Drugs ·Roopal Thakkar, Moti L. Kashyap, Andrew Lewin, Scott Krause, Ping Jiang, Robert J. Padley	18
9	Efficacy and Safety of a Potent and Selective Peroxisome Proliferator Activated Receptor Alpha Agonist in Subjects With Dyslipidemia and Type 2 Diabetes Mellitus 2008 ·The American Journal of Cardiology ·Steven G. Terra, Omar L. Francone, Charles F. Contant, Xiang Gao, Andrew Lewin, Tu T. Nguyen	9
10	Basal insulin or premix analogue therapy in type 2 diabetes patients 2007 ·European Journal of Internal Medicine ·Philip Raskin, Priscilla Hollander, Andrew Lewin, Robert A. Gabbay, Bruce W. Bode, Alan J. Garber	51
11	Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study 2007 ·Clinical Therapeutics ·Andrew Lewin, Robert Lipetz, (unknown), Sherwyn Schwartz	13
12	Selective Aldosterone Blockade with Eplerenone Reduces Albuminuria in Patients with Type 2 Diabetes 2006 ·Clinical Journal of the American Society of Nephrology ·Murray Epstein, Gordon H. Williams, Myron H. Weinberger, Andrew Lewin, Scott Krause, Robin Mukherjee, Rajiv Patni, Bruce Beckerman	353
13	Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial 2004 ·Clinical Therapeutics ·Andrew Lewin, Mark Kipnes, Luigi Meneghini, D. Plotkin, Inna Perevozskaya, Sukrut Shah, Darbie Maccubbin, Yale Mitchel, Jonathan A. Tobert	31
14	The JNC 7 Approach Compared to Conventional Treatment in Diabetic Patients With Hypertension: A Double‐Blind Trial of Initial Monotherapy vs. Combination Therapy 2004 ·Journal of Clinical Hypertension ·Jonathan C. Fox, (unknown), Santosh Sutradhar, Laura A. Demopoulos, Gilbert W. Gleim, Andrew Lewin, George L. Bakris	9
15	The evolving role of oral insulin in the treatment of diabetes using a novel RapidMist? System 2002 ·Diabetes/Metabolism Research and Reviews ·Pankaj Modi, Marko Mihic, Andrew Lewin	76
16	An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan 1998 ·Clinical Therapeutics ·Suzanne Oparil, Robert Guthrie, Andrew Lewin, Thomas Marbury, (unknown), Joseph Triscari, Jeffrey A. Witcher	78
17	Transdermal Clonidine as an Adjunct to Enalapril: An Evaluation of Efficacy and Patient Compliance 1992 ·The Journal of Clinical Pharmacology ·Donald J. Weidler, John D. Wallin, (unknown), D.H. Dillard, Andrew Lewin, Kandace M. Matzek	20
18	A Comparison of the Safety of Therapeutically Equivalent Doses of Isradipine and Diltiazem for Treatment of Essential Hypertension: An Alternative Viewpoint 1992 ·American Journal of Hypertension ·Henry R. Black, Andrew Lewin, Gerald H. Stein, (unknown), (unknown), B P Hamilton, Nicolaos E. Madias, Mahendr S. Kochar, (unknown), Jonathan L. Isaacsohn, (unknown), (unknown)	5
19	Comparison of guanfacine versus clonidine for efficacy, safety and occurrence of withdrawal syndrome in step-2 treatment of mild to moderate essential hypertension 1986 ·The American Journal of Cardiology ·Michael F. Wilson, Olga M. Haring, Andrew Lewin, (unknown), (unknown), (unknown), (unknown), Martin S. Roginsky, F. Gilbert McMahon, Paul I. Jagger, (unknown)	22
20	THE CHINESE VERSIONS OF MODERN ACUPUNCTURE 1973 ·Europe PMC (PubMed Central) ·Andrew Lewin	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact